A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial-Reference-Cited by-同舟云学术

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial

Published:2023-04-03 Issue:5 Volume:91 Page:413-425
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Puszkiel Alicja,You Benoit^ORCID,Payen Léa,Lopez Jonathan,Guitton Jérôme,Rousset Pascal,Fontaine Juliette,Péron Julien,Maillet Denis,Tartas Sophie,Bonnin Nathalie,Trillet-Lenoir Veronique,Colomban Olivier,Augu-Denechere Diane,Freyer Gilles,Tod Michel

Funder

Hospices Civils de Lyon

Ligue Contre le Cancer

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-023-04520-z.pdf

Reference39 articles.

1. Yap TA, Omlin A, de Bono JS (2013) Development of therapeutic combinations targeting major cancer signaling pathways. Proc Am Soc Clin Oncol 31:1592–1605. https://doi.org/10.1200/JCO.2011.37.6418

2. Frances N, Woloch C, Marouani H, Mercier C, Iliadis A (2012) Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients. Curr Top Med Chem 12:1665–1668

3. Garralda E, Dienstmann R, Tabernero J (2017) Pharmacokinetic/pharmacodynamic modeling for drug development in oncology. Am Soc Clin Oncol Educ B 37:210–215

4. Tanaka C, O’Reilly T, Kovarik JM, Shand N, Hazell K, Judson I et al (2016) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596–1602

5. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA et al (2011) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135–164